YOLFTbeta
Arecor Therapeutics PLC

Arecor Therapeutics PLC

AREC · LSE · Healthcare / Biotechnology

77.50GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close77.50
Open78.00
Day Range75.10 – 78.00
52-Week Range55.27 – 95.00
Volume57.04K
Market Cap27.37M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta-0.19
50-Day Avg71.42
200-Day Avg70.49

About

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Sarah Jennifer Howell Ph.D.
  • Employees33
  • HeadquartersChesterford Research Park, Little Chesterford, United Kingdom, CB10 1XL, UK
  • Websitehttps://arecor.com

Leadership

  • Dr. Sarah Jennifer Howell Ph.D.CEO & Executive Director · b. 1975
  • Mr. David J. EllamCFO & Executive Director · b. 1964
  • Dr. Jan Jezek Ph.D.Chief Scientific Officer
  • Mr. David GerringChief Development Officer

Financials

Income Statement

Currency: GBP2018-05-312019-05-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.35M747.67K1.89M1.70M1.16M2.40M4.57M5.05M1.71M
Growth (%)--44.62%+152.92%-10.23%-31.79%+107.51%+90.30%+10.50%-66.08%
Cost of Revenue-----341.00K3.32M3.51M663.00K
Gross Profit1.35M747.67K1.89M1.70M1.16M2.40M4.57M1.54M1.05M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%30.54%61.32%
Operating Expense2.75M3.60M4.58M5.13M7.13M14.06M13.75M12.24M5.72M
Operating Income-1.40M-2.85M-2.69M-3.43M-5.98M-11.66M-9.18M-10.70M-4.67M
Operating Margin-103.53%-381.85%-142.16%-201.93%-516.15%-485.23%-200.63%-211.70%-272.23%
EBITDA-1.22M-2.68M-2.61M-3.26M-6.27M-10.06M-8.39M-10.15M-4.45M
EBITDA Margin-90.71%-358.38%-138.07%-191.86%-541.19%-418.73%-183.47%-200.87%-259.68%
Net Income-1.12M-2.44M-2.19M-2.75M-6.17M-9.26M-8.55M-10.24M664.00K
Net Income Margin-82.90%-325.72%-115.79%-162.13%-532.73%-385.35%-187.05%-202.57%38.74%
R&D2.33M3.09M3.56M3.94M5.39M8.61M5.98M3.04M2.69M
R&D as % of Total Revenue172.55%412.65%188.51%231.89%465.11%358.43%130.70%60.18%157.18%
Interest Expense28.68K23.98K3.66K87.00K507.00K21.00K15.00K22.00K11.00K
Interest Expense % of Total Revenue2.12%3.21%0.19%5.12%43.78%0.87%0.33%0.44%0.64%

Balance Sheet

Currency: GBP2017-05-312018-05-312019-05-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.56M2.07M5.45M4.31M4.28M20.92M21.77M15.38M8.72M8.10M
Total Liabilities1.23M1.40M1.23M1.10M3.51M2.37M4.31M5.85M3.37M1.65M
Total Equity1.33M670.33K4.22M3.21M773.79K18.55M17.45M9.53M5.35M6.45M
Cash1.03M704.94K3.45M3.07M2.90M18.32M4.76M5.09M3.24M3.00M
Total Debt576.12K660.09K221.27K158.12K2.00M231.00K288.00K338.00K232.00K98.00K
Net Debt-452.19K-44.85K-3.23M-2.92M-903.46K-18.09M-4.48M-4.75M-3.01M-2.90M

Cash Flow

Currency: GBP2018-05-312019-05-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-492.57K-2.50M-458.80K-1.86M-5.45M-10.78M-5.84M-9.15M-2.29M
Investing Cash Flow-12.77K-64.55K-22.89K-49.32K-68.00K-7.99M6.52M1.72M2.38M
Financing Cash Flow216.73K5.32M-131.02K1.77M20.93M5.16M-180.00K5.65M-148.00K
Capital Expenditure12.92K73.13K32.30K52.29K69.00K345.00K151.00K23.00K99.00K
Free Cash Flow-505.49K-2.58M-491.10K-1.91M-5.52M-11.13M-5.99M-9.18M-2.39M
FCF to OCF102.62%102.92%107.04%102.82%101.27%103.20%102.59%100.25%104.32%

Earnings

Report DateSep 23, 2021Apr 25, 2022Sep 8, 2022Apr 20, 2023May 6, 2025Sep 25, 2025
EPS Estimate0.000.000.00-0.000.00
EPS Actual-0.06-0.17-0.16-0.16-0.15-0.07
Surprise------
TimingPre-marketPre-marketPre-marketPre-market--

Key Statistics & Ratios

Market Cap27.37M
Enterprise Value27.38M
Trailing P/E0.00
Forward P/E0.00
Price / Sales30.76
Price / Book5.18
EPS0.00
Book Value0.171
Revenue (TTM)890.00K
Gross Profit (TTM)503.00K
EBITDA-5.01M
Profit Margin21.35%
Operating Margin-1629.90%
Return on Equity-1.44%
Return on Assets-64.57%
Shares Outstanding37.76M
Shares Float20.91M
Beta-0.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%